Waxman to seek Medicaid prices for dual eligbles
Executive Summary
Legislation that would set Medicare Part D drug prices paid specifically for dual eligible beneficiaries at rates that were paid under Medicaid prior to being shifted to the federal prescription drug program is under development by House Oversight and Government Reform Committee Chairman Henry Waxman, D-Calif. The pending bill is an outgrowth of a report the committee released in July that said the government is paying 30 percent more for dual eligibles' drugs since drug coverage for the dual eligibles shifted from Medicaid to Medicare Part D under the Medicare Modernization Act (1"The Pink Sheet," July 28, 2008, p. 24). Brian Cohen, senior investigative counsel for the committee, said Sept. 23 during the AHIP annual Medicare and Medicaid conference that a bill could be introduced soon, but at the very latest early into the next Congress
You may also be interested in...
CBO Scores 15% Rebate For All Part D Brand Drugs In Health Care Report
The Congressional Budget Office has taken proposals for a required rebate on drugs for dual-eligible beneficiaries in Medicare Part D a step further by scoring a 15 percent rebate requirement for all brand drugs in the program
Republican Strategy To Protect Part D Raises Risks For Pharma
House Oversight and Government Reform Committee Republicans are attempting to deflect criticism of Medicare Part D drug expenditures by redirecting focus back to larger expenditures under Parts A and B
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.